The Dermatology Digest

Galderma recently released a new report highlighting six global aesthetic trends identified based on comprehensive trend-forecasting research conducted in collaboration with a network of aesthetic specialists and skincare influencers. TDD/JDNPPA?sat down with?Gerry Muhle, Galderma’s Head of Global Product Strategy, to find out what’s happening in aesthetics now, what may be coming down the pike, and how specialists can best prepare for it. https://lnkd.in/eZFT6K4R

Jerry Tan, MD, is joining Derm-Biome Pharmaceuticals, Inc.’s Scientific Advisory Board. Dr. Jerry Tan, is a #dermatologist in?Windsor, ON, the immediate past President of the Acne and Rosacea Society of Canada, co-chair of the Acne Core Outcomes Research Network (ACORN). https://lnkd.in/dWdkgJ26

Experts Drs. Raj Chovatiya and Matthew Zirwas speak at an educational symposium on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation. Watch here: https://lnkd.in/d6cqpv5g

Sonoma Pharmaceuticals, Inc. is relaunching its prescription #dermatology and #eyecare products lines. https://lnkd.in/dSKu3M92

Chris Sayed, MD, a dermatologist at the University of North Carolina at Chapel Hill’s HS Clinic in Durham, NC, discusses the role that bimekizumab-bkzx may play for adults with moderate-to-severe hidradenitis suppurativa (HS) now that it has the U.S. FDA’s nod for this chronic inflammatory skin condition. https://lnkd.in/d7hTqv7h

They say derm does it better. ?? What did YOU think of this recent WSJ article? The Wall Street Journal Shereene Idriss, MD https://lnkd.in/dptZBmeS

Thomas Casale, MD, a Professor of Medicine and Pediatrics and Chief of Clinical and Translational Research in the Division of Allergy/Immunology at the Morsani College of Medicine of the University of South Florida, reviews the data that supported the SBLA resubmission.??“We need more good therapies for these patients because of the big effect [that CSU has] their quality of life, their ability to sleep,??[and] the ability to interact with other people, so it’s very exciting that … the clinically meaningful and statistically significant efficacy demonstrated at 24 weeks in patients who were symptomatic despite the use of H1 antihistamines confirmed the results of the initial study and now led to the FDA reviewing this as another possible indication for this drug.” Watch here: https://lnkd.in/d6nWnN8n

Happy #BotoxDay! A few insights from Dr. David Shafer, below!

JUST IN: ?The US FDA has approved bimekizumab-bkzx (Bimzelx, UCB) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). https://lnkd.in/dgmezDZu

Interleukin-38 (IL-38) may drive the mechanisms underlying skin renewal, finds a study in?Cell Reports by Cell Press. A team from the University of Geneva has observed IL-38 for the first time in the form of condensates in keratinocytes. The presence of IL-38 in these aggregates is enhanced close to the skin’s surface exposed to atmospheric oxygen. This process could be linked to the initiation of programmed keratinocyte death. https://lnkd.in/dqW_aWPC